Cerulean制药 CERU 深 沪
等待开盘 10-23 09:30:00 美东时间
0.655
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.655
- 总市值 190.11万
- 52周最高 3.58
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.323
- 委 比 0.00%
- 总股本 290.24万
- 历史最高 10.87
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.323
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML
CERo Therapeutics has completed the first cohort of its Phase 1 clinical trial for CER-1236 in acute myeloid leukemia (AML) patients, observing consistent cell expansion without dose-limiting toxicities. The Dose Escalation Safety Committee has approved the initiation of Cohort 2 with an increased starting dose. The company also plans to provide an additional infusion to Cohort 1 patient based on encouraging pharmacokinetic data. CERo emphasizes ...
10-13 12:30
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma
Cellectar Biosciences announced initial results from the CLOVER-2 Phase 1b clinical trial of iopofosine I 131 in pediatric high-grade glioma (pHGG) patients. Patients receiving a minimum of 55 mCi achieved an average of 5.4 months PFS and 8.6 months OS, with all experiencing disease control. Three patients with additional dosing had an average PFS of 8.1 months and OS of 11.5 months. Iopofosine I 131 was well-tolerated with manageable hematologic...
06-11 12:05
CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company’s Lead Compound CER-1236
CERo Therapeutics Holdings, Inc. announced that two U.S. patent applications and one European patent application have been granted or allowed, significantly expanding the company's intellectual property portfolio. These include patents for chimeric TIM4 receptors, chimeric engulfment receptor molecules, and combination cellular immunotherapy compositions. CER-1236, the company's lead compound, is now supported by 18 issued patents and allowed app...
06-02 13:05
世纪睿科(01450.HK)获Golden Ocean Holdings Corp.折让71%提收购要约
原标题：世纪睿科(01450.HK)获Golden Ocean Holdings Corp.折让71%提收购要约 来源：格隆汇 格隆汇7月30日丨世纪睿科(0...
2021-07-30 21:35
